Todd Triplett

Assistant Professor (tenure track)

Texas Tech University Health Sciences Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Todd Triplett is an Assistant Professor (tenure track) at Texas Tech University of Health Sciences Center in the United States. His research focuses on immunotherapy, cancer biology, and the immune responses to neurological conditions, particularly in the context of COVID-19 and treatments for various cancers. Recent publications include studies on the immune trajectories in patients with neurological autoimmunity and the effects of novel inhibitors on tumor growth.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Cole Maguire

University of Texas at Austin

UNITED STATES

View details

Tamer Kaoud

Research Assistant Professor

University of Texas at Austin

UNITED STATES

View details

Chang-Han Lee

Assistant Professor

Seoul National University

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Todd Triplett

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy

Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy

Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy

EXPLORING THE POTENTIAL OF T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) FOR GENERATING LEUKEMIA-SPECIFIC T CELL RESPONSES THAT CAN BE THERAPEUTICALLY HARNESSED WITH IMMUNOTHERAPY

Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results

Current methods in translational cancer research

Tumor-associated myeloid cells provide critical support for T-ALL

Current methods in translational cancer research

Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

CLASS SPECIFIC HDAC INHIBITION DIFFERENTIALLY AFFECTS THE FUNCTION OF SPECIFIC T CELL SUBSETS

Collaborators (3)

Cole Maguire

Tamer Kaoud

Chang-Han Lee

Make your next move.